MindWalk (NASDAQ:HYFT) versus Ginkgo Bioworks (NYSE:DNA) Head-To-Head Contrast

Ginkgo Bioworks (NYSE:DNA) and MindWalk (NASDAQ:HYFT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Risk and Volatility

Ginkgo Bioworks has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500. Comparatively, MindWalk has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Insider & Institutional Ownership

78.6% of Ginkgo Bioworks shares are owned by institutional investors. Comparatively, 6.7% of MindWalk shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by insiders. Comparatively, 6.8% of MindWalk shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Ginkgo Bioworks and MindWalk”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15 million	4.88	-$312.76 million	($5.01)	-2.46
MindWalk	$11.24 million	5.57	-$10.11 million	($0.26)	-5.15

MindWalk has lower revenue, but higher earnings than Ginkgo Bioworks. MindWalk is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ginkgo Bioworks and MindWalk’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%
MindWalk	-105.11%	-133.26%	-77.78%

Analyst Recommendations

This is a summary of current ratings and target prices for Ginkgo Bioworks and MindWalk, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2	2	0	0	1.50
MindWalk	1	1	2	1	2.60

Ginkgo Bioworks currently has a consensus target price of $6.33, suggesting a potential downside of 48.67%. MindWalk has a consensus target price of $5.00, suggesting a potential upside of 273.13%. Given MindWalk’s stronger consensus rating and higher probable upside, analysts clearly believe MindWalk is more favorable than Ginkgo Bioworks.

Summary

MindWalk beats Ginkgo Bioworks on 8 of the 15 factors compared between the two stocks.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.